Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of AMG 570 in Healthy Subjects

Next Previous
Search
Trial Profile

A Randomized, Double Blind Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of AMG 570 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rozibafusp alfa (Primary)
  • Indications Rheumatoid arthritis; Systemic lupus erythematosus
  • Focus Adverse reactions; First in man
  • Sponsors Amgen

    • Most Recent Events

    • 17 Mar 2021 Results of pharmacokinetic and PK/PD from phase I studies in healthy and RA subjects (NCT02618967, NCT03156023) presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 07 Sep 2018 Status changed from active, no longer recruiting to completed.
    • 16 Aug 2018 Planned End Date changed from 15 Aug 2018 to 5 Sep 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top